News 2007

February 2007	Support for climate initiatives In February 2007, the Global Roundtable on Climate Change made an urgent appeal to politicians to formulate serious and scientifically founded targets for reducing greenhouse gas emissions in the period after expiry of the Kyoto Protocol. Bayer also signed the position paper “The Path to Climate Sustainability.” A few weeks before, in January 2007, Bayer and a number of other companies publicly presented the project “3C: Combat Climate Change.” To slow down climate change, the initiative sets out to help politicians set a global framework for reducing emissions that ensures fair competition for all companies .
March 2007	Stakeholders questioned As a globally operating chemical and pharmaceuticals group, Bayer is constantly confronted with a wide variety of requirements. To document and evaluate them systematically, we conducted in March 2007 a worldwide online survey among some 500 stakeholders. You can read more about the survey and the results here .
2007	Publications on Trasylol® Two separate observational studies reported on a possible correlation between the administration of Trasylol®, our product for use during open-heart surgery, and severe renal dysfunction and vasoconstriction (myocardial infarction and stroke). A follow-up study to one of them reported on a possible correlation between administration of this product and increased long-term mortality. Based on our study data and many years of experience with Trasylol®, Bayer believes that this product is a safe and effective medicine when used correctly. We are cooperating closely with the relevant regulatory authorities to resolve the questions that have arisen.
April 2007	Fight against Chagas disease Bayer HealthCare supports the World Health Organization (WHO) in its fight against Chagas disease. A new agreement to provide 2.5 million tablets of the drug Lampit® and additional financial support was signed in April 2007. As a result, the supply of Lampit® is secure for the next five years. This is the third agreement between Bayer HealthCare and the who to improve the supply of Chagas patients in Latin America with the effective medication – irrespective of the economic situation of the patients. Chagas disease is a fatal parasitic infection that is widespread in many countries of Central and South America.

Last updated: June 29, 2007 Bookmark this page E-mail this page Copyright © Bayer AG